Hematologic Cancers

Great advances have been made in our understanding of how myeloproliferative neoplasms (MPNs)-essential thrombocythemia, polycythemia vera, myelofibrosis (MF)-result in overproduction of inflammatory markers, according to Holly L. Geyer, MD, Assistant Professor of Medicine, Division of Hospital Internal Medicine, Mayo Clinic, Scottsdale, AZ, and colleagues. Read More ›

Recent advancements in the treatment of multiple myeloma (MM) have led to significant improvements in patient outcomes, including unprecedented survival rates. Read More ›

With recent evidence pointing to a link between chronic inflammation and Philadelphia-negative myeloproliferative neoplasms, essential thrombocythemia, polycythemia vera, and myelofibrosis, Hans Carl Hasselbalch, MD, DMSc, and Mads Emil Bjorn, MD, PhDc, Department of Hematology, Roskilde Hospital, University of Copenhagen, Denmark, recently published a review article purporting that myeloproliferative neoplasms are inflammatory diseases. Read More ›

Welcome to our first newsletter in the Conquering the Multiple Myeloma Continuum series, which focuses on adherence to oral medications in patients with multiple myeloma (MM). In this first newsletter, you will learn about some of the major causes of nonadherence that patients and their providers face. Read More ›

IDH mutations have been observed among various groups of patients, including those with glioblastoma multiforme, grade 2 and 3 gliomas, and secondary glioblastomas, as well as patients with acute myeloid leukemia. However, limited data exist among patients with Philadelphia-negative myeloproliferative neoplasms. Read More ›

Although there have been several trial-based studies on the use of ruxolitinib in patients with lower-risk myelofibrosis (MF), Keith L. Davis, MA, Senior Director of Health Economics at RTI Health Solutions and colleagues sought to conduct a study in the real-world setting. Read More ›

The advent of imatinib (Gleevec; Novartis Pharmaceuticals) was considered a near miracle for the treatment of chronic myeloid leukemia (CML). Read More ›

Routine surveillance imaging of asymptomatic patients in first remission after treatment for diffuse large B-cell lymphoma offers little clinical benefit at substantial cost, according to Scott F. Huntington, MD, of Abramson Cancer Center, University of Pennsylvania, Philadelphia, and colleagues. Read More ›

Ibrutinib represents a major advance in the treatment of previously treated chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), having achieved dramatic and sometimes durable responses in both diseases. Although ibrutinib is approved by the US Food and Drug Administration for both CLL and MCL, judging by the show of hands at the Oncology Nursing Society 39th Annual Congress, the majority of oncology nurses have not yet had experience with it. Read More ›

Page 5 of 10

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: